Item Type | Name |
Academic Article
|
DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease.
|
Academic Article
|
Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays.
|
Academic Article
|
Lazarus rises: islet regeneration in the 21st century.
|
Academic Article
|
Becaplermin and necrobiosis lipoidicum diabeticorum: results of a case control pilot study.
|
Academic Article
|
Insulin-specific tolerance in diabetes.
|
Academic Article
|
Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes.
|
Academic Article
|
Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes.
|
Academic Article
|
Insulin treatment prevents diabetes mellitus but not thyroiditis in RT6-depleted diabetes resistant BB/Wor rats.
|
Academic Article
|
Prediabetes: prediction and prevention trials.
|
Academic Article
|
Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop.
|
Academic Article
|
HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes.
|
Academic Article
|
Type 1 diabetes.
|
Academic Article
|
T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading.
|
Academic Article
|
CD4+CD25high regulatory T cells in human autoimmune diabetes.
|
Academic Article
|
Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups.
|
Academic Article
|
Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population.
|
Academic Article
|
Secondary attack rate of type 1 diabetes in Colorado families.
|
Academic Article
|
Optimizing insulin therapy in pregnant women with type 1 diabetes mellitus.
|
Academic Article
|
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
|
Academic Article
|
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.
|
Academic Article
|
Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes.
|
Academic Article
|
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
|
Academic Article
|
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.
|
Academic Article
|
Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes.
|
Academic Article
|
Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems.
|
Academic Article
|
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
|
Academic Article
|
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.
|
Academic Article
|
Editorial: cystic fibrosis.
|
Academic Article
|
Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes.
|
Academic Article
|
Impact of insulin lispro on HbA1c values in insulin pump users.
|
Academic Article
|
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
|
Academic Article
|
Immunology of Diabetes Society T-Cell Workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative.
|
Academic Article
|
Immunology of Diabetes Society T-Cell Workshop: HLA class II tetramer-directed epitope validation initiative.
|
Academic Article
|
Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.
|
Academic Article
|
Cytokine and immunosuppressive therapies of type 1 diabetes mellitus.
|
Academic Article
|
Testing the NKT cell hypothesis of human IDDM pathogenesis.
|
Academic Article
|
Dysregulated Toll-like receptor-induced interleukin-1? and interleukin-6 responses in subjects at risk for the development of type 1 diabetes.
|
Academic Article
|
No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity.
|
Academic Article
|
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil.
|
Academic Article
|
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
|
Academic Article
|
Immune therapy and ?-cell death in type 1 diabetes.
|
Academic Article
|
Transient myocardial perfusion abnormalities in diabetic patients: a prospective study using thallium exercise tolerance testing.
|
Academic Article
|
Mouse and man: multiple genes and multiple autoantigens in the aetiology of type I DM and related autoimmune disorders.
|
Academic Article
|
T cell receptor restriction of diabetogenic autoimmune NOD T cells.
|
Academic Article
|
Inflammatory markers and diabetic retinopathy in type 1 diabetes.
|
Academic Article
|
Diagnosis and treatment of pre-insulin dependent diabetes.
|
Academic Article
|
Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes.
|
Academic Article
|
A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin.
|
Academic Article
|
Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.
|
Academic Article
|
Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump.
|
Academic Article
|
Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
|
Academic Article
|
Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
|
Academic Article
|
A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes.
|
Academic Article
|
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
|
Academic Article
|
Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes.
|
Academic Article
|
Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells.
|
Academic Article
|
Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.
|
Academic Article
|
Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes.
|
Academic Article
|
Type 1 diabetes intervention trials 2007: where are we and where are we going?
|
Academic Article
|
Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software.
|
Academic Article
|
Altered Toll-like receptor signaling pathways in human type 1 diabetes.
|
Academic Article
|
Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.
|
Academic Article
|
Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes.
|
Academic Article
|
Time lag characterization of two continuous glucose monitoring systems.
|
Academic Article
|
Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8.
|
Academic Article
|
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
|
Academic Article
|
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
|
Academic Article
|
Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation.
|
Academic Article
|
Comparison of cryopreservation methods on T-cell responses to islet and control antigens from type 1 diabetic patients and controls.
|
Academic Article
|
Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8? T cells in type 1 diabetes.
|
Academic Article
|
Approaches to prevention and treatment of IDDM in animal models.
|
Concept
|
Diabetes Mellitus, Type 1
|
Concept
|
Diabetes Mellitus, Type 2
|
Academic Article
|
Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform.
|
Academic Article
|
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
|
Academic Article
|
B-lymphocyte depletion with rituximab and ?-cell function: two-year results.
|
Academic Article
|
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
|
Academic Article
|
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
|
Academic Article
|
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
|
Academic Article
|
Chromogranin A is a T cell antigen in human type 1 diabetes.
|
Academic Article
|
MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice.
|
Academic Article
|
a1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1? responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.
|
Academic Article
|
Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline.
|
Academic Article
|
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
|
Academic Article
|
Anti-thymocyte globulin/G-CSF treatment preserves ? cell function in patients with established type 1 diabetes.
|
Academic Article
|
Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects.
|
Academic Article
|
Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients.
|
Academic Article
|
Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes.
|
Academic Article
|
Development of Autoimmune-Mediated ? Cell Failure After Total Pancreatectomy With Autologous Islet Transplantation.
|
Academic Article
|
What defines disease in an age of genetics and biomarkers?
|
Academic Article
|
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
|
Academic Article
|
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
|
Academic Article
|
Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.
|
Academic Article
|
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2?year results of a randomised trial.
|
Academic Article
|
ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.
|
Academic Article
|
Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.
|
Academic Article
|
Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?
|
Academic Article
|
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
|
Academic Article
|
Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.
|
Academic Article
|
Predominance of DR3 in Somali children with type 1 diabetes in the twin cities, Minnesota.
|
Academic Article
|
The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.
|
Grant
|
IMMUNOTHERAPY TRIAL IN NEW ONSET TYPE 1 DIABETES
|
Grant
|
Human TCR/HLA Transgenic Mice to Prevent T1DM
|
Grant
|
TrialNet: Diabetes Type 1 Prevention Trial
|
Grant
|
TrialNet: Diabetes Type 1 Prevention
|
Academic Article
|
Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.
|
Academic Article
|
Understanding and preventing type 1 diabetes through the unique working model of TrialNet.
|
Academic Article
|
Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet.
|
Academic Article
|
Combinatorial detection of autoreactive CD8+ T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell Workshop.
|
Academic Article
|
Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles.
|
Academic Article
|
Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes.
|
Academic Article
|
Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.
|
Academic Article
|
Learning From Past Failures of Oral Insulin Trials.
|
Academic Article
|
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.
|
Academic Article
|
Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes.
|
Academic Article
|
Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk for Type 1 Diabetes.
|
Academic Article
|
Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes.
|
Academic Article
|
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7?years from diagnosis.
|
Academic Article
|
Rationally designed small molecules to prevent type 1 diabetes.
|
Academic Article
|
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
|
Academic Article
|
Biomarker Discovery in Pre-Type 1 Diabetes; Th40 Cells as a Predictive Risk Factor.
|
Academic Article
|
Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes.
|
Academic Article
|
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
|
Academic Article
|
Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes.
|
Academic Article
|
Single-Cell Analysis of CD4 T Cells in Type 1 Diabetes: From Mouse to Man, How to Perform Mechanistic Studies.
|
Academic Article
|
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
|
Academic Article
|
Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes.
|
Academic Article
|
Clinical trial data validate the C-peptide estimate model in type 1 diabetes.
|
Academic Article
|
Risk of Islet and Celiac Autoimmunity in Cotwins of Probands With Type 1 Diabetes.
|
Academic Article
|
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.
|
Academic Article
|
Endotypes in T1D: B lymphocytes and early onset.
|
Academic Article
|
Advances in Diabetes Treatment - Once-Weekly Insulin.
|
Academic Article
|
T-cell responses to hybrid insulin peptides prior to type 1 diabetes development.
|
Academic Article
|
Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.
|
Academic Article
|
Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes.
|
Academic Article
|
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
|
Academic Article
|
Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.
|
Academic Article
|
Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes.
|
Academic Article
|
Temporal development of T cell receptor repertoires during childhood in health and disease.
|
Academic Article
|
Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.
|
Academic Article
|
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
|
Academic Article
|
Identification of an anergic BND cell-derived activated B cell population (BND2) in young-onset type 1 diabetes patients.
|
Academic Article
|
Measuring anti-islet autoimmunity in mouse and human by profiling peripheral blood antigen-specific CD4 T cells.
|
Academic Article
|
Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.
|
Academic Article
|
Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves ?-Cell Function.
|
Academic Article
|
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.
|